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Abstract
Aims/hypothesis Insulin resistance and type 2 diabetes
have been associated with ectopic lipid deposition. This
study investigates the derangements in postprandial lipid
handling in liver and skeletal muscle tissue at different
stages during the pathogenesis of type 2 diabetes in a
rat model.
Methods Four groups (n06) of male Zucker diabetic fatty
rats were used for this study: prediabetic fa/fa rats and
healthy fa/+ littermates at the age of 6 weeks, and diabetic
fa/fa rats and healthy fa/+ littermates at the age of 12 weeks.
In vivo 1H-[13C] magnetic resonance spectroscopy measure-
ments were performed in liver and tibialis anterior muscle at
baseline and 4, 24 and 48 h after oral administration of 1.5 g
[U-13C]algal lipid mixture per kilogram body weight. Total
and 13C-labelled intracellular lipid contents were determined
from the magnetic resonance spectra.
Results In both prediabetic and diabetic rats, total lipid
contents in muscle and liver were substantially higher than
in healthy controls and this was accompanied by a 2.3-fold
greater postprandial lipid uptake in the liver (p<0.001).
Interestingly, in prediabetic rats, skeletal muscle appeared
to be protected from excess lipid uptake whereas after
developing overt diabetes muscle lipid uptake was 3.4-fold
higher than in controls (p<0.05). Muscle lipid use was
significantly lower in prediabetic and diabetic muscle, in-
dicative of impairments in lipid oxidation.
Conclusions/interpretation In vivo postprandial lipid hand-
ling is disturbed in both liver and skeletal muscle tissue in
prediabetic and diabetic rats, but the uptake of dietary lipids
in muscle is only increased after the development of overt
diabetes.
Keywords Carbon-13 . Insulin resistance .
Intrahepatocellular lipids . Intramyocellular lipids . Lipid
uptake . Magnetic resonance spectroscopy . Prediabetes .
Type 2 diabetes . ZDF rat
Abbreviations
En% Energy per cent
FAT/CD36 Fatty acid translocase CD36
GC-C-IRMS Gas chromatography–combustion–isotope
ratio mass spectrometry
ICL Intracellular lipids
IHCL Intrahepatocellular lipids
IMCL Intramyocellular lipids
LASER Localisation by adiabatic selective refocusing
MRS Magnetic resonance spectroscopy
POCE Proton-observed, carbon-edited
SWAMP Sequence for water suppression with
adiabatic modulated pulses
TA Tibialis anterior
TAG Triacylglycerol
ZDF Zucker diabetic fatty
Introduction
Insulin resistance and type 2 diabetes have been associated
with excess lipid accumulation in non-adipose tissues such
as skeletal muscle [1, 2] and liver [3, 4]. The mechanistic
link between intracellular lipid overload and insulin
resistance is believed to reside in the accumulation of
lipid-derived intermediates, such as diacylglycerols and
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ceramides, which trigger activation of novel protein kinase
C isozymes leading to impairments in insulin signalling [5].
It remains unknown, however, whether the excess storage of
lipids in insulin-resistant muscle and liver is a consequence
of greater lipid uptake from the circulation, decreased lipid
use through oxidation, release and/or secretion, or a combi-
nation of both.
Results from studies on intracellular lipid handling in
insulin-resistant skeletal muscle and liver tissue are far from
consistent. Lipid uptake in muscle of insulin-resistant and
type 2 diabetic individuals and corresponding animal mod-
els has been reported to be either higher (mostly but not
exclusively in postprandial conditions) [6–15], similar
[16–20] or lower (mostly but not exclusively in postabsorp-
tive conditions) [9, 21–28] when compared with insulin-
sensitive controls. Lipid oxidation in insulin-resistant or
type 2 diabetic muscle has also been reported to be either
lower [9, 17, 18, 20–25, 29] or unchanged [6, 7, 14, 19]
when compared with healthy controls. Data on lipid uptake
in insulin-resistant and type 2 diabetic liver tissue are scarce
and have predominantly been obtained from animal models,
showing either an increase [12, 21, 30] or no significant
difference [8, 20, 31] compared with controls. Liver lipid
secretion, as measured by the production of VLDL particles,
is generally reported to be greater in an insulin-resistant or
type 2 diabetic state [32–34]. Differences in study design,
such as the nutritional state (postprandial vs postabsorptive
conditions), can only explain part of the discrepancy in the
literature. In addition, other factors, such as the stage of type 2
diabetes pathogenesis and the methodology applied to assess
lipid handling, are likely to contribute to the apparent
inconsistency.
Recently, we introduced the application of 1H-[13C] mag-
netic resonance spectroscopy (MRS) in combination with
the oral administration of 13C-labelled lipids to determine in
vivo postprandial lipid partitioning in skeletal muscle and
liver tissue in rodents [35]. 1H-[13C] MRS indirectly detects
the 13C-labelled lipids through the attached 1H nuclei. After
correction for the natural abundance of 13C, this allows the
amount of lipids stored in the tissue originating from the
dietary 13C-labelled lipids to be quantified. MRS is non-
invasive and does not involve harmful radiation, allowing
repeated measurements to follow the time course of uptake
and depletion of 13C-labelled lipids in multiple tissues. We
have shown that in healthy rats the uptake of 13C-labelled
lipids was about tenfold higher in liver than in skeletal
muscle [35].
In this study we applied the 1H-[13C] MRS technique in
prediabetic and diabetic rat models with the aim of gaining
greater insight into the derangements in liver and skeletal
muscle lipid handling at different stages during the patho-
genesis of type 2 diabetes. Total and 13C-labelled lipid
concentrations were measured in liver and skeletal muscle
tissue at baseline, and at 4, 24 and 48 h after the oral
administration of [U-13C]algal lipid mixture. Based on pre-
vious observations, we hypothesised that postprandial lipid
handling is disturbed in both liver and skeletal muscle tissue
of prediabetic rats, and that these disturbances are further
exacerbated following the development of overt type 2
diabetes.
Methods
Animals and study design Four groups (n06) of male
Zucker diabetic fatty (ZDF) rats (Charles River Labora-
tories, Sulzfield, Germany) were used for this study:
(1) obese, prediabetic fa/fa rats at the age of 6 weeks;
(2) lean, healthy fa/+ littermates at the age of 6 weeks;
(3) obese, diabetic fa/fa rats at the age of 12 weeks and
(4) lean, healthy fa/+ littermates at the age of 12 weeks
[36, 37]. The rats were housed in pairs at 20°C and 50%
humidity, on a 12 h light–dark cycle with free access to Purina
5008 diet (19 energy per cent [En%] from fat, 54 En% from
carbohydrates and 27 En% from protein; SM R/M modified
5008 diet; Ssniff Spezialdiäten, Soest, Germany) and water
during the entire period of the experiment. All experi-
mental procedures were reviewed and approved by the
local institutional animal care committee (Maastricht
University, Maastricht, the Netherlands).
Before the administration of 13C-labelled lipids, 1H-[13C]
MRS measurements were carried out on all rats to determine
total (12C+13C) and 13C-enriched intracellular lipid (ICL)
concentrations in the tibialis anterior (TA) muscle (intra-
myocellular lipids, IMCL) and liver (intrahepatocellular lip-
ids, IHCL) at baseline. Two days later, rats were orally
administered 1.5 g [U-13C]algal lipid mixture (13C enrich-
ment >98%; fatty acid composition: 53% palmitic acid, 9%
palmitoleic acid, 28% oleic acid, and 6% linoleic acid;
Cambridge Isotope Laboratories, Andover, MA, USA) per
kg body weight. 1H-[13C] MRS measurements were per-
formed at 4, 24 and 48 h after administration of 13C-labelled
lipids.
Blood samples were taken from the vena saphena after
each MRS experiment and were used for the determination
of plasma glucose, NEFA and triacylglycerol (TAG)
concentrations.
MRS experiments During the MRS experiments, rats were
anaesthetised using 1.5–2.5% isoflurane (IsoFlo; Abbott
Laboratories, Maidenhead, UK). Body temperature was
maintained at 37±1°C using heating pads. All MRS experi-
ments were performed on a 6.3 T horizontal Bruker MR
system (Bruker, Ettlingen, Germany). In each rat, localised
1H-[13C] MRS was performed first on a 3.5×3.5×3.5 mm3
(in fa/+ rats) or 3×3×3 mm3 (in fa/fa rats) voxel placed in
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the TA muscle (Fig. 1a,b) and, after repositioning, on a 4×
2×4 mm3 voxel in the median lobe of the liver (Fig. 1c,d)
using the LASER-POCE method as described previously
[35]. For each voxel, 64 water-suppressed LASER-POCE
experiments, consisting of 16 averages each, were per-
formed serially in an interleaved fashion with the 13C-edit-
ing pulse turned on every other experiment. An
unsuppressed water spectrum, consisting of 16 averages,
was recorded from the same voxel and was used as internal
reference.
MRS data analysis Spectra from the 32 LASER-POCE
experiments with and without 13C editing were added sep-
arately and the difference spectrum was calculated using
Matlab (R2009b; Mathworks, Natick, MA, USA). Water
and ICL methylene (ICL-CH2 signal at 1.3 ppm) peak areas
were quantified from the unsuppressed and suppressed spec-
tra, respectively, using the jMRUI software package [38] as
described previously [39]. Total (12C+13C) and 13C-labelled
ICL levels were determined from the LASER-POCE spectra
without 13C editing and the difference spectra, respectively,
and are presented as a percentage of the unsuppressed water
signal measured in the same voxel. The average relative
13C enrichment determined at baseline was used to correct
the 13C-labelled ICL levels at 4, 24 and 48 h after
13C-labelled lipid administration for natural abundance of
13C. Previously, we have shown that the in-vivo 1H-[13C]
MRS determination of 13C enrichment of IHCLwas in agree-
ment with the ex-vivo analysis by gas chromatography–
combustion-isotope ratio mass spectrometry (GC-C-IRMS)
and that the 1.1% natural abundance of 13C could be reliably
determined in both IMCL and IHCL pools [35].
Plasma analysis Blood samples were collected in K-EDTA-
coated tubes at baseline and at 4, 24 and 48 h after
13C-labelled lipid administration, centrifuged for 10 min at
1,000 g, and portioned plasma volumes were frozen in
liquid nitrogen and stored at −80°C. Concentrations of plas-
ma glucose, NEFA and TAG were determined using an
automatic glucometer (FreeStyle; Abbott, Abbott Park, IL,
USA), the NEFA-HR(2) kit (Wako Chemicals, Neuss, Ger-
many) and the serum TAG determination kit (Sigma-Aldrich,
Zwijndrecht, the Netherlands), respectively.
Statistics All data (n06 per group) are expressed as means±
SEM. Data were analysed using mixed-model repeated-
measures ANOVA with time point (baseline and 4, 24 and
48 h post) as the within-subject factor, and age (6 and
12 weeks) and genotype (fa/+ and fa/fa) as between-
subject factors. Only if the interaction term between the
factors was found to be significant, the effect of each factor
was analysed separately using one-way ANOVA (time
point) or unpaired Student’s t tests (age and genotype).
Bonferroni corrections were applied when appropriate. Sta-
tistical analyses were performed using the IBM SPSS sta-
tistics software package (SPSS, version 19, Chicago, IL,
USA). The level of significance was set at p<0.05.
Results
Body weight The body weight of fa/fa rats was 18%
higher than that of fa/+ rats (p<0.001), independent
of age (Table 1). Rats at 12 weeks of age were 95% heavier
than rats at 6 weeks of age (p<0.001), independent of geno-
type. The amount of 13C-labelled lipids that was administered
to the rats was scaled to body weight (Table 1).
Plasma glucose, NEFA and TAG Results of the plasma
analyses are shown in Table 2. Plasma glucose concentrations
were higher in fa/fa rats compared with fa/+ rats independent
of time point both at 6 (12.2±0.7 vs 7.3±0.3 mmol/l,
p<0.001) and 12 (18.9±0.8 vs 6.9±0.3 mmol/l, p<0.001)
weeks of age. In diabetic fa/fa rats at 12 weeks of age, plasma
glucose was 50% higher when compared with the prediabetic
fa/fa rats at 6 weeks of age independent of time point
(p<0.01). The administration of 13C-labelled lipids did not
affect plasma glucose levels after 4, 24 and 48 h in any group
(p00.296). At 6 weeks of age, plasma NEFA concentrations
did not differ between prediabetic fa/fa rats and their control
littermates (p00.820). In contrast, at 12 weeks of age, plasma
NEFA concentrations in diabetic fa/fa rats were 86% higher
than in fa/+ rats independent of time point (p<0.05). Plasma
NEFA at 4 and 24 h after the administration of 13C-labelled
lipids was not significantly different from baseline, but at 48 h
after 13C-labelled lipid administration it had decreased by as
Fig. 1 T1-weighted transversal images of a fa/+ rat left hindlimb with
a 3.5×3.5×3.5 mm3 voxel in the TA muscle (a), a fa/fa rat left
hindlimb with a 3×3×3 mm3 voxel in the TA muscle (b), a fa/+ rat
abdomen with a 4×2×4 mm3 voxel in the median lobe of the liver (c)
and a fa/fa rat abdomen with a 4×2×4 mm3 voxel in the median lobe
of the liver (d)
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much as 60±6% when compared with the earlier time points
in all groups. Plasma TAG concentrations were higher in fa/fa
rats compared with fa/+ rats, independent of age and time
point (1.64±0.10 vs 0.43±0.02 mmol/l, p<0.001). The ad-
ministration of 13C-labelled lipids did not affect plasma TAG
levels after 4, 24 and 48 h in any group.
MRS data Figure 2 displays typical examples of water-
suppressed LASER-POCE spectra acquired from TA muscle
and liver at 4 h after the administration of 13C-labelled lipids in
a healthy fa/+ rat and a diabetic fa/fa rat at 12 weeks of age.
The lipid methylene signal at 1.30 ppm in the normal
1H spectra without the 13C-editing pulse was used for quanti-
fication of total (12C+13C) IMCL and IHCL. The difference
spectra, resulting from the subtraction of the experiments with
and without the 13C-editing pulse, only contain signals from
1H-13C coupled resonances and were used to determine the
13C enrichment of the IMCL and IHCL pools.
Total IMCL and IHCL concentrations at baseline and 4,
24 and 48 h after oral administration of the [U-13C]algal
lipid mixture in fa/+ and fa/fa rats at 6 and 12 weeks of age
are shown in Fig. 3. Data are expressed as percentage of the
unsuppressed water signal measured in the same voxel. At
both ages, total IMCL and IHCL content were higher in
fa/fa rats compared with fa/+ rats. In fa/fa rats, IMCL
content was 73% higher at 12 weeks compared with 6 weeks
(p<0.001), whereas in fa/+ rats IMCL was 43% lower at
12 weeks than at 6 weeks (p<0.001). IHCL content was
48% higher at 12 weeks of age compared with 6 weeks,
independent of genotype (p<0.05). The administration of
13C-labelled lipids did not affect total IMCL and IHCL
levels, except for a very slight decrease in IMCL in all
groups at 48 h after administration, which is probably relat-
ed to the decrease in plasma NEFA concentration at this
time point.
The relative 13C enrichments of IMCL and IHCL mea-
sured at baseline were 1.19±0.04% and 1.39±0.06%, re-
spectively, both independent of genotype and age. These
values were used to correct 13C-labelled IMCL and IHCL
levels at 4, 24 and 48 h after the administration of
13C-labelled lipids for natural abundance of 13C and the
results are shown in Fig. 4. Thus, 13C-enriched IMCL and
Table 1 Body weight of rats and amount of 13C-labelled lipid mixture administered
Body weight/amount of lipid administered 6 weeks 12 weeks
fa/+ fa/fa fa/+ fa/fa
Body weight (g) 166±7 190±12*** 319±10††† 374±11***,†††
13C-labelled algal lipid mixture (mg) 247±26 286±43*** 478±15††† 563±17***,†††
Data are means ± SEM
***p<0.001, compared with fa/+; ††† p<0.001, compared with 6 weeks
Table 2 Plasma glucose, NEFA
and TAG concentrations at
baseline and 4, 24 and 48 h after
oral administration of the
13C-labelled lipid mixture to rats
Data are means ± SEM
*p<0.05, ***p<0.001 compared
with fa/+; ††p<0.01, compared
with 6 weeks; ‡‡‡p<0.001,
comparedwith baseline; §p<0.05,
compared with 4 h post lipid
administration; ¶p<0.05,
compared with 24 h post lipid
administration
Variable 6 weeks 12 weeks
fa/+ fa/fa fa/+ fa/fa
Plasma glucose (mmol/l)
Baseline 7.0±0.3 11.8±1.3*** 7.5±0.3 17.7±1.7***,††
4 h post 7.2±0.4 11.0±0.9*** 6.5±0.7 18.9±2.2***,††
24 h post 6.9±0.1 13.5±0.8*** 7.0±0.2 20.7±0.3***,††
48 h post 8.1±1.2 12.6±2.2*** 6.5±0.7 18.4±1.3***,††
Plasma NEFA (mmol/l)
Baseline 0.32±0.03 0.38±0.06 0.24±0.04 0.44±0.04*
4 h post 0.28±0.04 0.29±0.04 0.22±0.06 0.50±0.09*
24 h post 0.35±0.05 0.26±0.05 0.27±0.07 0.34±0.05*
48 h post 0.15±0.05‡‡‡,§,¶ 0.13±0.02‡‡‡,§,¶ 0.08±0.02‡‡‡,§,¶ 0.26±0.08*,‡‡‡,§,¶
Plasma TAG (mmol/l)
Baseline 0.47±0.05 1.54±0.30*** 0.45±0.02 1.52±0.20***
4 h post 0.40±0.03 1.66±0.34*** 0.52±0.05 1.51±0.23***
24 h post 0.33±0.05 1.28±0.18*** 0.36±0.05 1.39±0.09***
48 h post 0.42±0.05 1.97±0.31*** 0.47±0.06 2.16±0.34***
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IHCL concentrations in Fig. 4 represent the amount of lipids
stored in muscle and liver originating from the administered
13C-labelled lipids.
At 6 weeks of age, 13C-labelled IMCL content at 4 h after
administration of 13C-labelled lipids was 31% lower in fa/fa
rats than in fa/+ rats (p<0.05), indicating a lower postprandial
muscle lipid uptake in prediabetic rats compared with controls
(Fig. 4a). In fa/+ rats at 12 weeks of age, 13C-labelled IMCL
content 4 h post lipid administrationwas 44% lower compared
with the content in fa/+ rats at 6 weeks (p<0.05), implying
that in control rats muscle lipid uptake decreased with ageing
(Fig. 4a,b). In contrast, in diabetic fa/fa rats at 12weeks of age,
13C-labelled IMCL at 4 h post lipid administration was 217%
higher compared with prediabetic fa/fa rats at 6 weeks
(p<0.01), resulting in a 243% higher 13C enrichment of
IMCL at 4 h in comparison with fa/+ controls of the same
age (p<0.05) (Fig. 4a,b). In all groups, the 13C enrichment of
IMCL decreased as a function of time between 4 and 48 h after
administration. However, in contrast to control fa/+ rats,
13C-labelled IMCL in fa/fa rats at both ages only started to
decline at 48 h post lipid administration and did not signifi-
cantly decrease between 4 and 24 h, indicating a prolonged
uptake or a decreased turnover of the 13C-labelled lipids in
prediabetic and diabetic muscle (Fig. 4a,b).
At 4 h after the oral administration of 13C-labelled lipids,
the 13C enrichment of IHCL was 2.3-fold greater in fa/fa rats
compared with fa/+ rats (p<0.001), independent of age,
implying that postprandial liver lipid uptake was greater in
both prediabetic and diabetic rats compared with controls
(Fig. 4c,d). At 12 weeks of age, 13C-labelled IHCL content
was ∼50% higher compared with the content at 6 weeks of
age (p<0.05), independent of genotype and time point
(Fig. 4c,d). In all groups, the 13C enrichment of IHCL at
24 and 48 h was lower than at 4 h after the administration of
13C-labelled lipids (p<0.001), but it was always higher in
fa/fa rats than in fa/+ rats (p<0.001) (Fig. 4c,d).
Discussion
This study aimed to clarify whether intracellular lipid accu-
mulation in insulin-resistant and diabetic liver and skeletal
muscle tissue is a consequence of increased lipid uptake,
decreased lipid use, or a combination of both. Using non-
invasive 1H-[13C] MRS combined with the oral administra-
tion of a 13C-labelled lipid mixture [35], we showed that in
vivo postprandial lipid uptake in liver in both prediabetic
and diabetic rats was greater than the uptake in healthy,
insulin-sensitive controls, while liver lipid use was not af-
fected. Whereas skeletal muscle appeared to be protected
from excess lipid uptake in the prediabetic state, muscle
lipid uptake was massively increased following the devel-
opment of overt type 2 diabetes. Skeletal muscle lipid turn-
over was significantly reduced in prediabetic and diabetic
rats.
In this study, we used the ZDF rat as an animal model of
type 2 diabetes. We, as well as others, have previously
shown that fa/fa ZDF rats progress from prediabetes to overt
type 2 diabetes in a highly predictable age-dependent fash-
ion [37, 40]. At the age of 6 weeks, fa/fa rats are in an
insulin-resistant, prediabetic state characterised by normal
plasma glucose levels in fasting conditions, slightly in-
creased plasma glucose levels in the fed state, normal plas-
ma NEFA but elevated plasma insulin and TAG levels [37,
40], which was confirmed in the present study. Between
8 and 10 weeks of age, fa/fa rats progress from a normogly-
caemic–hyperinsulinaemic to a hyperglycaemic–hyperinsu-
linaemic state [37, 40]. In this study, we confirmed that the
fa/fa rats at 12 weeks of age developed overt type 2 diabetes.
Heterozygous fa/+ rats remained normoglycaemic and nor-
moinsulinaemic and served as healthy controls [37, 40].
In liver of prediabetic and diabetic fa/fa rats, the lipid
content was 5.6-fold greater when compared with the
healthy controls and this was accompanied by a 2.3-fold
greater dietary lipid uptake in the liver 4 h after lipid ad-
ministration. These data are in accordance with previous
observations of elevated lipid uptake in insulin-resistant
Fig. 2 Typical examples of LASER-POCE spectra from TA muscle (a,
b) and liver (c, d) from a healthy fa/+ rat (a, c) and a diabetic fa/fa rat
(b, d) at 12 weeks of age. Spectra were acquired 4 h after the oral
administration of 1.5 g [U-13C]algal lipid mixture per kg body weight.
LASER-POCE spectra without 13C editing, with 13C editing and the
calculated difference spectra containing only 13C-coupled 1H resonan-
ces (5× magnification) are shown. Peak annotations: tCr, total creatine;
EMCL, extramyocellular lipids; Cho, choline
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and diabetic liver [8, 12, 20, 21, 30]. During periods of high
lipid influx, such as during the immediate postprandial
period, the liver acts as a systemic lipid buffer by taking
up NEFA from the spillover pathway and chylomicron
remnants, which are later re-secreted back into the circula-
tion as VLDL [41, 42]. It has been suggested that in the
insulin-resistant state, a greater proportion of meal derived
fatty acids may be handled by the liver in the postprandial
period [42], which is consistent with our data of increased
hepatic lipid uptake in prediabetic and diabetic rats. Relative
decreases in 13C-labelled IHCL content between 4 and 48 h
after administration of 13C-labelled lipids were similar for
all groups, indicating that liver lipid turnover was largely
unaffected in prediabetic and diabetic rats when compared
with the healthy controls.
Between 6 and 12 weeks of age, liver lipid content
increased in both fa/fa and fa/+ rats by 48%, which was
accompanied by a 62% higher uptake of dietary lipids in the
liver, also independent of genotype. These increases in liver
lipid content and uptake can therefore be ascribed to a
general effect of ageing and are not necessarily specific for
the transition from prediabetes to overt type 2 diabetes in fa/
fa rats. In addition, the greater liver lipid uptake at 12 weeks
could be due to the twofold higher amount of 13C-labelled
lipids that was administered to the rats at 12 weeks com-
pared with rats at 6 weeks of age. However, at 4 h after
intake of the 13C-labelled lipids, the relative increase in liver
lipid uptake in fa/+ rats between 12 and 6 weeks of age was
much larger than in fa/fa rats. This might indicate that in
diabetic rats the maximum lipid buffer capacity of the liver
is reached during the early postprandial period (<4 h), ex-
posing other tissues, such as skeletal muscle, to increased
plasma TAG and NEFA fluxes.
In addition to the steatotic liver, prediabetic fa/fa rats also
had 2.3-fold higher intracellular lipid levels in skeletal mus-
cle when compared with the healthy controls. However, the
greater IMCL content in prediabetic rats was not associated
with excess postprandial muscle lipid uptake. In contrast to
the highly elevated postprandial lipid uptake in liver, the
uptake of dietary lipids in muscle at 4 h after intake was
31% lower in prediabetic rats when compared with the
healthy controls. This result is in quantitative agreement
with data from previous studies in insulin-resistant obese
Zucker rats using orally administered 14C-labelled lipids
[20, 21]. However, in contrast to these reports and our
own data, other studies have shown an increased postpran-
dial muscle lipid uptake in insulin-resistant individuals and
animals [8, 11, 15]. In addition, in vitro measurements in
Fig. 3 Total (12C+13C) intracellular lipid content in TA muscle
(IMCL; a, b) and liver (IHCL; c, d) of fa/+ rats (black bars) and
fa/fa rats (white bars) at 6 (a, c) and 12 (b, d) weeks of age measured
at baseline and at 4, 24 and 48 h after the oral administration of [U-13C]
algal lipid mixture (n06 per group). Data are expressed as a mean
percentage of the unsuppressed water signal±SEM. IMCL content in
fa/+ rats and fa/fa rats at 12 weeks was significantly different from
6 weeks, independent of time point (p<0.05). IHCL content was
significantly higher at 12 weeks than at 6 weeks, independent of
genotype and time point (p<0.05). ***p<0.001, compared with fa/+
rats; †p<0.05, compared with baseline; ‡p<0.05, compared with 24 h
post lipid administration
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isolated muscle preparations and giant sarcolemmal vesicles
yielded increased lipid uptake rates in muscle from insulin-
resistant obese individuals and obese Zucker rats [7, 10, 13,
14]. Whereas fatty acid concentrations in these in vitro
experiments were identical for insulin-resistant and control
muscle, muscle of prediabetic rats in our in-vivo studies was
exposed to fourfold higher plasma TAG levels compared
with controls. The amount of 13C-labelled lipids that was
administered to the rats was scaled to body weight, but was
only 1.2-fold higher in prediabetic rats than in controls.
Therefore, the 13C-labelled lipids are likely to be more
diluted in the plasma of prediabetic rats compared with
controls, which might have resulted in an underestimation
of the in vivo muscle lipid uptake in prediabetic rats. Un-
fortunately, we lack information about the 13C enrichment of
plasma TAG, because it was not possible to extract the lipid
fraction from the small blood samples obtainable from rats,
which is required for GC-C-IRMS. The lower lipid uptake
in muscle of prediabetic rats as observed in the current study
suggests that, after the initial buffering by the liver, more of
the dietary lipids are shunted toward adipose tissue storage.
Previous studies have indeed shown that upregulation of
adipocyte lipid uptake is an early event in ZDF rats [31]
and that in obese Zucker rats the majority of dietary lipids
are directed toward storage in adipose tissue [20, 21].
Between 6 and 12 weeks of age, intracellular lipid con-
tent in skeletal muscle decreased by 43% in fa/+ rats,
whereas it increased by 73% in fa/fa rats. These age-
dependent changes in IMCL content are in excellent agree-
ment with our previous study in ZDF rats [40]. The de-
creased IMCL content in fa/+ rats at 12 weeks of age was
accompanied by a 44% lower dietary lipid uptake at 4 h after
administration compared with fa/+ rats at 6 weeks of age. In
diabetic fa/fa rats at 12 weeks, on the other hand, the
increased IMCL content was associated with a 217% higher
dietary lipid uptake at 4 h compared with prediabetic fa/fa
rats at 6 weeks of age. As a result, postprandial lipid uptake
in muscle of diabetic rats was 3.4-fold higher when com-
pared with controls, which is in accordance with previous
reports of increasedmuscle lipid uptake in patients with type 2
diabetes during postprandial conditions [6, 9, 12]. In contrast,
during postabsorptive conditions, muscle lipid uptake has
generally been found to be decreased in type 2 diabetes
patients [9, 22, 23, 25].
The elevated uptake of dietary lipids in diabetic muscle is
in sharp contrast with the lower muscle lipid uptake in
prediabetic rats when compared with insulin-sensitive con-
trols. Our data on liver lipid uptake suggest that in diabetic
rats the maximum lipid buffer capacity of the liver has been
reached, which might expose skeletal muscle to greater
Fig. 4 13C-enriched intracellular lipid content in TA muscle (IMCL; a,
b) and liver (IHCL; c, d) of fa/+ rats (black bars) and fa/fa rats (white
bars) at 6 (a, c) and 12 (b, d) weeks of age determined at 4, 24 and 48 h
after the oral administration of [U-13C]algal lipid mixture (n06 per
group). Data are expressed as a mean percentage of the unsuppressed
water signal±SEM. 13C-enriched IMCL content in fa/+ rats at 4 h
was significantly lower at 12 weeks than at 6 weeks (p<0.05),
whereas in fa/fa rats 13C-enriched IMCL content was significantly
higher at 12 weeks than at 6 weeks for each time point (p<0.05).
13C-enriched IHCL content was significantly higher at 12 weeks
than at 6 weeks, independent of genotype and time point (p<0.05).
*p<0.05, compared with fa/+ rats; †p<0.05, compared with 4 h
post lipid administration; ‡p<0.05, compared with 24 h post lipid
administration
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plasma TAG and NEFA fluxes in the immediate postpran-
dial period, leading to an increase in muscle lipid uptake.
Alternatively, the increased postprandial muscle lipid uptake
after the progression from prediabetes to overt type 2 dia-
betes could also be due to changes at the level of skeletal
muscle itself. In type 2 diabetes, hyperinsulinaemia
increases skeletal muscle lipoprotein lipase activity [43],
which could lead to an increased fatty acid delivery to the
diabetic muscle. Fatty acid transport into the myocyte is
largely mediated by proteins, of which fatty acid translocase
CD36 (FAT/CD36) plays a key role [44]. The increased fatty
acid uptake in giant sarcolemmal vesicles from muscle of
type 2 diabetic patients and obese Zucker rats could, how-
ever, not be explained by an increased production of FAT/
CD36 [7, 10]. Instead, the increase in fatty acid transport
was associated with an increased abundance of FAT/CD36
at the plasma membrane [7, 10]. Our findings of reduced
muscle lipid uptake in prediabetic rats and increased lipid
uptake in muscle of rats with overt type 2 diabetes suggest
that during the progression from prediabetes to diabetes, the
expression and/or plasmalemmal content of FAT/CD36 has
been increased. Indeed, in giant sarcolemmal vesicles from
red muscle of ZDF rats there was a marked increase in both
protein production and plasmalemmal content of FAT/CD36
between 6 and 12 weeks of age [45]. However, in white
muscle this upregulation was completely absent [45]. Rat
TA muscle is composed of a red region and a white region
and the MRS voxel contained both red and white muscle.
Therefore, while our results might not be universally true for
all muscle types, they might be representative for mixed
muscles, such as most human skeletal muscles.
In contrast to findings in healthy control rats, 13C-labelled
IMCL in prediabetic and diabetic rats did not significantly
decrease between 4 and 24 h after the administration of
13C-labelled lipids, indicating lower lipid oxidation. Daily
activity levels are very similar in fa/+ and fa/fa rats [46]
and therefore the lower lipid turnover in fa/fa rats is likely
the result of an impairment in lipid oxidation. These
results are in accordance with previous reports of reduced
lipid oxidation in insulin-resistant and type 2 diabetic
muscle [9, 17, 18, 20–25, 29].
In conclusion, we have shown that in both prediabetic
and diabetic rats, total lipid contents in skeletal muscle and
liver are substantially higher than in healthy controls. In the
liver, this is accompanied by a highly elevated in-vivo
postprandial lipid uptake in both prediabetic and diabetic
rats. In contrast, skeletal muscle of prediabetic rats is pro-
tected from excess lipid uptake and muscle lipid uptake is
only elevated following the development of overt diabetes.
Our data suggest that the accumulation of lipids in predia-
betic muscle is mainly attributed to impaired lipid oxidation,
whereas lipid uptake is strongly increased following the
development of an overt type 2 diabetic state.
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